A Phase 3 interventional study of Lantus (insulin glargine [rDNA origin] injection) and Metformin in Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2011-01-11.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing Insulin Glargine in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus.
Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, this one is the 25th largest by enrollment, is one of 2 that started in 2001, is one of 25 in phase 3, and was the 1st registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 81 studies testing Insulin Glargine in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–50 · Women only
Medical University of Warsaw · Sites in Poland
Ages 18+
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 80 across the 81 interventional studies. Of the 75 that completed or were terminated, 31 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 81 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
33 studies in Diabetes Mellitus by Sanofi: none open now, none under way, none of them phase 3. Of 33 finished, 0 (0%) have results posted.
Among the 33 studies in Diabetes Mellitus by Sanofi, this one is the 15th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2001, is one of 12 in phase 3, and was the 2nd registered.
Sanofi’s Diabetes Mellitus studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 33 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy
Time frame: During the Study Conduct
Occurrence of hypoglycemia
Time frame: During the study conduct
Change in fasting plasma glucose
Time frame: During the study conduct
Percentage of patients achieving HbA1C less than or equal to 7%
Time frame: During the study conduct
Time to glycemic control
Time frame: During the study conduct
Change in body weight
Time frame: During the study conduct
Change in serum lipid profile
Time frame: During the study conduct
The record gives a start of Nov 2001, a primary completion of Nov 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Metformin · 2,4-thiazolidinedione